Investigating whether different doses of Fruitflow have equal impact on blood platelets in different healthy subjects

Evaluation of the equivalence of different doses of Fruitflow® in affecting blood platelet aggregation and thrombin generation capacity in a pilot study in healthy subjects

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN53447583

Enrollment

Registered

2021-02-24

Start date

2018-05-01

Completion date

Unknown

Last updated

2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reduction of platelet hyperactivity in healthy subjects Circulatory System Qualitative platelet defects

Interventions

The study sets out to examine whether 5 different doses of Fruitflow (0, 30, 75, and 300 mg) are equivalent to the standard daily dose of 150mg. The study will follow a double-blind randomised crossov

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Male subjects 2. No history of cardiovascular disease 3. Aged =30 years 4. Normal haemostatic measurements 5. Normal platelet aggregation response to adenosine diphosphate (ADP) agonist 6. Not taking any supplements or medications known to affect platelet function, without a suitable washout period

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
Platelet aggregation in response to optimised adenosine diphosphate (ADP) agonist concentration, measured using light transmission aggregometry at baseline and 24 h	—

Secondary

Measure	Time frame
Thrombin generation capacity measured by fluorogenic substrate generation at baseline and 24 h	—

Countries

Norway

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 20, 2026